A Study of HQP1351 in Patients With GIST or Other Solid Tumors
← catalyst calendarNCT03594422 · readout ≤ 499 d
Sponsored by Ascentage Pharma Group Inc. (industry) · AAPG — their whole pipeline →. With HealthQuest Pharma Inc..
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
100estimated
Sites
6
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2018-07-11 | actual | When the study began enrolling |
| Primary completion | Dec 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2018-07-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Gastrointestinal Stromal Tumor (GIST)
- Solid Tumor, Adult
Intervention
- Drug: HQP1351
Primary outcome
what the primary-completion date above is the date OFSafety and tolerance
measured 30 days after the last dose of HQP1351
Publications
- PMID 41184234 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AAPG's whole pipeline · Catalyst calendar · Every registered study · What changed